Search Results

Prasugrel 100 mg  | 98.62%

TargetMol

Prasugrel is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.

More Information Supplier Page

Pazopanib 100 mg  | 99.84%

TargetMol

Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.

More Information Supplier Page

Vardenafil 200 mg  | 99.88%

TargetMol

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from […]

More Information Supplier Page

Vardenafil 100 mg  | 99.88%

TargetMol

Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from […]

More Information Supplier Page

Moroxydine hydrochloride 100 mg  | Purity Not Available

TargetMol

Moroxydine hydrochloride is a synthetic antiviral drug chemically belonging to the series of the heterocyclic biguanidines. It has antiviral activity and is helpful in the prevention and treatment of influenza.

More Information Supplier Page

Pazopanib 25 mg  | 99.84%

TargetMol

Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.

More Information Supplier Page